

# A word from the AWMSG Chairman

Dr Stuart Linton MB ChB, BSc, FRCP (UK)



**AWTTC**

All Wales Therapeutics  
& Toxicology Centre

# AWMSG meetings: Rules of engagement!


- A meeting of minds – which should be challenging but not confrontational
- Remit of NMG – assess clinical effectiveness and cost effectiveness, with input from clinical experts – producing a preliminary appraisal recommendation
- Remit of AWMSG – ...to additionally consider budget impact and societal issues



# of AWMMSG...

- Advise the Welsh Government of future developments in healthcare to assist in its strategic planning.
- Advise the Welsh Government on the development and implementation of a prescribing strategy for Wales.
- Develop timely, independent and authoritative advice on new medicines via HTA process
- Develop prescribing resources and monitor prescribing indicators
- (By no means an exhaustive list!)

# AWMSG medicine appraisals



# Summary of appraisal recommendations:

## In summary

- Since 2003 AWMSG has carried out 341 appraisals (as of November 1<sup>st</sup> 2017)
- 287 (84%) have resulted in a full or optimised AWMSG recommendation



# AWMSG and NICE

- Since 2003, 40 medicines recommended by AWMSG have been subsequently recommended by NICE, enabling timely access to clinically and cost-effective medicines for patients in NHS Wales
- The median time advantage gained in Wales for those medicines which received a positive AWMSG recommendation which was subsequently superseded by NICE advice was **16.5 months** (range 2-67 months)
- 8 appraisals by AWMSG have been completed (6 recommended) which have a NICE appraisal in progress






# Some barriers to engagement?

- **Insufficient cost-effectiveness data at licensing stage**
- **ICER expected to be too high**
- **Previous 'no' from AWMSG for another licensed indication for the medicine**
- **Small numbers of patients in Wales**
- **Limited impact of AWMSG modifiers**
- **Decision not to promote medicine in Wales**
- **Lack of resources to engage in Wales**

# Modifying/removing the barriers...



- Problem

- Insufficient cost-effectiveness data
- Small numbers
- ICER expected to be too high
- Delay in NICE decision unacceptable to Welsh NHS

## Solution



Rare disease/CAPIG process  
Limited submission process

Option of Welsh PAS  
? Eligibility for end of life criteria  
(numbers now removed)

One-Wales process



# Medicines Optimisation resources published during 2016-2017



**SUPPORTING TO PERSISTENT PAIN RESOURCES**

**SUMMARY OF CLINICAL RECOMMENDATIONS**

- 1. Clinical history** is a resource for advice and guidance for patients to ensure optimal use of their medicines and to ensure that the medicines they are taking are safe and effective.
- 2. Clinical history** is a resource for advice and guidance for patients to ensure optimal use of their medicines and to ensure that the medicines they are taking are safe and effective.
- 3. Clinical history** is a resource for advice and guidance for patients to ensure optimal use of their medicines and to ensure that the medicines they are taking are safe and effective.

**MANAGEMENT OF PERSISTENT PAIN**

**CLINICAL HISTORY**

**CLINICAL HISTORY**

**CLINICAL HISTORY**



**Key Messages - Managing Persistent Pain**

1. Managing persistent pain is a challenge for many patients and healthcare professionals. It is important to ensure that patients are given the best possible chance of achieving optimal pain relief.
2. The **Wales Pain Management Strategy** provides a framework for the management of persistent pain. It is important to ensure that patients are given the best possible chance of achieving optimal pain relief.
3. Further investigation may be required to ensure that patients are given the best possible chance of achieving optimal pain relief.

**Key Messages - Non-pharmacological management**

1. Non-pharmacological management is an important part of the management of persistent pain. It is important to ensure that patients are given the best possible chance of achieving optimal pain relief.
2. Cognitive Behavioural Therapy (CBT) can be used to help patients manage their pain. It is important to ensure that patients are given the best possible chance of achieving optimal pain relief.
3. Relaxation techniques can be used to help patients manage their pain. It is important to ensure that patients are given the best possible chance of achieving optimal pain relief.

**Key Messages - Treatment of Neuropathic Pain**

1. Neuropathic pain is a type of pain that is caused by damage to the nerves. It is important to ensure that patients are given the best possible chance of achieving optimal pain relief.
2. The **Wales Neuropathic Pain Management Strategy** provides a framework for the management of neuropathic pain. It is important to ensure that patients are given the best possible chance of achieving optimal pain relief.
3. Further investigation may be required to ensure that patients are given the best possible chance of achieving optimal pain relief.

**Key Messages - Strong Opioids**

1. Strong opioids are a type of painkiller that is used to treat severe pain. It is important to ensure that patients are given the best possible chance of achieving optimal pain relief.
2. The **Wales Strong Opioid Management Strategy** provides a framework for the management of strong opioids. It is important to ensure that patients are given the best possible chance of achieving optimal pain relief.
3. Further investigation may be required to ensure that patients are given the best possible chance of achieving optimal pain relief.

**All Wales Medicines Strategy Group**  
Grip Strategaeth Meddygiaethau Cymru Cyfan

## Medicines Management Resource for Chronic Kidney Disease

**All Wales Medicines Strategy Group**  
Grip Strategaeth Meddygiaethau Cymru Cyfan

## Educational Pack: Material to Support Appropriate Prescribing of Hypnotics and Anxiolytics across Wales

**All Wales Medicines Strategy Group**  
Grip Strategaeth Meddygiaethau Cymru Cyfan

## Dry Eye Syndrome Guidance

**All Wales Medicines Strategy Group**  
Grip Strategaeth Meddygiaethau Cymru Cyfan

## CEPP National Audit - Medicines Management for Chronic Kidney Disease

**All Wales Medicines Strategy Group**  
Grip Strategaeth Meddygiaethau Cymru Cyfan

## Vitamins for Babies, Children, and Pregnant and Breastfeeding Women

**All Wales Medicines Strategy Group**  
Grip Strategaeth Meddygiaethau Cymru Cyfan

## Safeguarding Users of Opioid Patches by Standardising Patient/Caregiver Counselling

**All Wales Medicines Strategy Group**  
Grip Strategaeth Meddygiaethau Cymru Cyfan

## Prescribing of Atrial Fibrillation and Atrial Flutter in Wales

**All Wales Medicines Strategy Group**  
Grip Strategaeth Meddygiaethau Cymru Cyfan

## Prescribing of Low Molecular Weight Heparin in Wales

**All Wales Medicines Strategy Group**  
Grip Strategaeth Meddygiaethau Cymru Cyfan

## Guidance for Partnership Working Between NHS Organisations, Primary Care Organisations, the Pharmaceutical Industry and Allied Commercial Sector in Wales

**All Wales Medicines Strategy Group**  
Grip Strategaeth Meddygiaethau Cymru Cyfan

## Monitoring Usage in Wales of Medicines Appraised by NICE and AWMWG

# National Prescribing Indicators



# Some highlights of 2016/17...

- NICE re-accreditation...
- ‘I am delighted to advise you that NICE is happy to renew accreditation of the process used by AWMSG to produce final appraisal recommendations’

NICE: October 2017





# Some highlights of 2016/17...

- Introduction of the New Treatment Fund for Wales

- HBs

... are now required to make new medicines recommended by the National Institute for Health and Care Excellence (NICE) and the All-Wales Medicines Strategy Group (AWMSG) available **as quickly as reasonably practicable and certainly within two months of the recommendation;**

...are expected to introduce new medicines recommended by NICE within two months of the first publication of the Final Appraisal Determination rather than waiting for the final Technology Appraisal Guidance which is published following the appeal period

New cancer medicines recommended for an interim period by NICE will also be available in Wales within the same two month timeframe, provided the manufacturer offers NHS Wales the same or similar package, including price as NHS England



# Highlights of 2002....



## Establishment of AWMSG....







# AWMSG 15<sup>th</sup> ANNIVERSARY CONFERENCE



# ...and a look to the year ahead

- Ensuring AWMSG appraisal process remains:
  - Robust
  - Timely
  - An efficient use of finite resources
  - Fit for purpose
- Consideration of a Welsh response to changes to NICE process
- Review of orphan and ultra orphan process in process
- Five-year strategy: *“Supporting prudent prescribing to obtain the best outcomes from medicines for patients in Wales”*



# AWMSG strategy



- AWMSG Five year strategy 2013-2018:  
    ‘Improving the patient’s experience of medicines in Wales’
- Aligned with Welsh Government’s publication ‘Together for Health’
- Key areas:
  - Improving health – medicines appraisals and prescribing guidance
  - One system for health
  - Fully integrated network of care
  - Aiming at excellence
  - Transparency of performance
  - Partnership with the public
  - Making every penny count
- Report will be published next year detailing performance against each of the key areas






# **AWMSG strategy main highlights**

- Strengthened partnership with the public – development of a Patient and Public Involvement Group (PAPIG) and Citizen's Jury on antibiotic resistance
- Developed and monitored National Prescribing Indicators, leading to improvements against targets and a reduction in variation in prescribing within Wales
- Produced and endorsed national guidelines, audits, and educational bulletins
- Delivered prudent prescribing workshops



# AWMSG strategy 2018 - 2023



- Currently out for consultation
- Aim – to build on the success of the previous strategy
- Supports Welsh Government’s initiative ‘*Healthcare that fits the needs and circumstances of patients and avoids wasteful care*’
- Aligned to the following principles:
  - Achieve health and wellbeing with the public, patients and professionals as equal partners through co-production
  - Care for those with the greatest health need first, making the most effective use of all skills and resources
  - Do only what is needed, no more, no less; and do no harm
  - Reduce inappropriate variation using evidence-based practices consistently and transparently



# Thank you



**AWTTC**  
All Wales Therapeutics  
& Toxicology Centre